TAK-733

Unknown Manufacturer

TAK-733 has been used in trials studying the treatment of Advanced Metastatic Melanoma, Advanced Nonhematologic Malignancies, and Advanced Non-hematologic Malignancies.

Generate AI report

Overview

TAK-733 has been used in trials studying the treatment of Advanced Metastatic Melanoma, Advanced Nonhematologic Malignancies, and Advanced Non-hematologic Malignancies.

Technical identifiers

Chemical Formula: C₁₇H₁₅F₂IN₄O₄
CAS Number: 1035555-63-5
UNII ID: 5J61HSP0QJ

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

ADMINISTRATION OF A RAF INHIBITOR AND A MEK INHIBITOR IN THE TREATMENT OF MELANOMA
US 2015126533 A1Applicant: TAKEDA PHARMACEUTICALPriority: 2013
CN
US
2 publications
REC-4881 (TAK-733) FOR USE IN TREATING OR PREVENTING COLORECTAL CANCER AND RELATED DISEASES
WO 2025147555 A1Applicant: RECURSION PHARMACEUTICALS INCPriority: 2024
CN
WO
2 publications
Compositions and methods for treating vascular anomalies, nevus sebaceous syndrome, epidermal nevi, and neurofibromas
US 12336997 B2Applicant: CHEMISTRY RXPriority: 2023
US
2 publications

Drugs